ASCO 2015 | Current clinical perspectives on targeted therapy and immunotherapy for melanoma
Caroline Robert
At the 2015 American Society of Clinical Oncology (ASCO) Annual Meeting, Caroline Robert, MD, PhD, from Institut Gustave Roussy, Villejuif, France, considers the impact of available and emerging targeted therapies and immunotherapies on the current treatment landscape in melanoma.
Related videos
4:00 Lifileucel in patients with advanced melanoma
Sunandana Chandra
4:02 PRADO: personalized response-driven surgery and adjuvant therapy in stage III melanoma
Sunandana Chandra
4:08 Updates from COMBI-AD: dabrafenib and trametinib for melanoma
Axel Hauschild
3:05 Producing patient-specific tumor-reactive T-cells
Chiara Cattaneo
1:27 Health-related QoL in ipilimumab treated advanced melanoma survivors
Christian Blank
